Teva Pharma Guides FY24 Revenue Above Estimates; Intends To Divest API Business - Update

RTTNews | 468天前
Stocktwits
Teva Pharma Guides FY24 Revenue Above Estimates; Intends To Divest API Business - Update

(RTTNews) - While reporting financial results for the fourth quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) initiated its adjusted earnings and revenue guidance for the full-year 2024.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.20 to $2.50 per share on revenues between $15.7 billion and $16.3 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.42 per share on revenues of $15.57 billion for the year. Analysts' estimates typically exclude special items.

The company also announced its intention divest its API business (including its R&D, manufacturing and commercial activities) through a sale, which divestment is expected to be completed in the first half of 2025.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

标签: TEVA
Stocktwits
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | 405天前
Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Says Generic Version Of Forteo Approved In U.S

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced Friday the approval of a generic version of Forteo in the United States. Forteo had annual sales of $609 million as of July 2023, according to IQVIA data.
RTTNews | 543天前
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the third quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 552天前
Teva Pharma Boosts FY23 Revenue Outlook - Update

Teva Pharma Boosts FY23 Revenue Outlook - Update

While reporting financial results for the second quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings guidance for the full-year 2023, while raising annual revenue outlook.
RTTNews | 650天前
Teva Pharma Reaffirms FY23 Outlook - Update

Teva Pharma Reaffirms FY23 Outlook - Update

While reporting financial results for the first quarter on Wednesday, Teva Pharmaceutical Industries Ltd (TEVA) reaffirmed its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews | 734天前
Teva Recalls FENTANYL Buccal Tablets CII

Teva Recalls FENTANYL Buccal Tablets CII

Teva Pharmaceuticals USA is recalling specific lots of various strengths of FENTANYL Buccal Tablets CII to the consumer level citing a labeling error, the U.S. Food and Drug Administration said. The recall has been initiated because safety updates were omitted in the product insert/medication guide that are provided with these recalled lots.
RTTNews | 743天前
Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Appoints Eric Hughes As Chief Medical Officer

Teva Pharmaceutical Industries Ltd. (TEVA) announced Friday the appointment of Dr. Eric Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, New Jersey.
RTTNews | 1047天前
FTSE 100 Modestly Higher In Cautious Trade

FTSE 100 Modestly Higher In Cautious Trade

U.K. stocks are up in positive territory a little past noon on Tuesday, although gains are just modest as investors make cautious moves, choosing to wait for more news on the economic as well as trade front.
RTTNews | 41分钟前
工具
经济日历
Market Hours
Interest Rates
Holidays Calendar
外汇市场
外汇波动率
外汇相关性
外汇新闻
forex analysis
COT数据
流动性
外汇计算器
外汇热力图
Indicators Heatmap
社区
社区
系统
最受欢迎的系统
策略
竞赛
外汇图表
外汇情绪
展望指标
评论
经纪人
Prop Trading Firms
VPS服务
信号提供者
EA编程服务
Affiliate Programs
PAMM经纪人服务
返利计划服务
交易平台
专家顾问
加密货币交易所
Trading Courses
经纪人
外汇点差
外汇经纪商报价
外汇经纪商掉期
外汇经纪商交易量
外汇经纪商促销 Press Release
平台
小工具
功能
API
RSS
Stock Portfolio
Affiliate Software
高级图表
支持
常见问题
帮助
联系我们
报告一个错误！
关于我们
博客
© 2025 Myfxbook Ltd. All Rights Reserved.
高风险警告：外汇交易具有高风险，可能不适合所有投资者。 杠杆创造了额外的风险和损失风险。 在您决定进行外汇交易之前，仔细考虑您的投资目标、经验水平和风险承受能力。 您可能会损失部分或全部的初始投资。不要投资您无法承受损失的钱。 对自己进行与外汇交易有关的风险教育，如果您有任何问题，请向独立的财务或税务顾问咨询。 任何数据和信息都是"按原样"提供的，仅仅是为了提供信息，并不打算用于交易目的或建议。 过去的业绩并不代表未来的结果。